Philippe Kolh of the University Hospital of Liege, Belgium, poses the question: what effect has the SYNTAX trial had on coronary artery disease intervention in Europe? He reviews the trial, examines its guidelines, and discusses the importance of risk models.
For information on how the SYNTAX trial has influenced practice in the United States, click here.
This presentation was originally given during the SCTS Ionescu University program at the 2015 Annual Meeting of the Society for Cardiothoracic Surgery in Great Britain and Ireland. This content is published with the permission of SCTS. Please click here for more information on SCTS educational programs.
1 Comment
great